Strs Ohio lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 9.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 189,111 shares of the company’s stock after selling 18,829 shares during the period. Strs Ohio’s holdings in Zoetis were worth $8,975,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in the stock. Renaissance Technologies LLC raised its stake in shares of Zoetis by 398.6% in the first quarter. Renaissance Technologies LLC now owns 1,413,100 shares of the company’s stock worth $62,643,000 after buying an additional 1,129,700 shares during the period. Legal & General Group Plc raised its stake in shares of Zoetis by 0.9% in the first quarter. Legal & General Group Plc now owns 2,104,616 shares of the company’s stock worth $93,293,000 after buying an additional 18,063 shares during the period. York Capital Management Global Advisors LLC bought a new stake in shares of Zoetis during the first quarter worth $49,823,000. Raymond James Trust N.A. raised its stake in shares of Zoetis by 5.0% in the second quarter. Raymond James Trust N.A. now owns 5,909 shares of the company’s stock worth $281,000 after buying an additional 281 shares during the period. Finally, Nordea Investment Management AB raised its stake in shares of Zoetis by 0.7% in the second quarter. Nordea Investment Management AB now owns 24,432 shares of the company’s stock worth $1,160,000 after buying an additional 163 shares during the period. 93.12% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Zoetis Inc. (NYSE:ZTS) traded up 1.94% during mid-day trading on Friday, reaching $52.01. 3,971,569 shares of the company traded hands. The company has a market capitalization of $25.75 billion, a P/E ratio of 40.51 and a beta of 1.01. The stock’s 50-day moving average is $51.26 and its 200-day moving average is $48.34. Zoetis Inc. has a 52 week low of $38.26 and a 52 week high of $52.64.
Zoetis (NYSE:ZTS) last issued its earnings results on Wednesday, August 3rd. The company reported $0.49 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.05. The business had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. Zoetis had a net margin of 13.15% and a return on equity of 77.58%. The business’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.43 earnings per share. On average, equities analysts predict that Zoetis Inc. will post $1.91 EPS for the current fiscal year.
A number of research analysts recently issued reports on the stock. Bank of America Corp. assumed coverage on shares of Zoetis in a research report on Thursday. They set a “buy” rating and a $60.00 target price for the company. Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $53.00 target price for the company in a research report on Wednesday, June 15th. Citigroup Inc. boosted their target price on shares of Zoetis from $50.00 to $53.00 and gave the company a “neutral” rating in a research report on Thursday, August 4th. Credit Suisse Group AG restated an “outperform” rating and set a $60.00 target price on shares of Zoetis in a research report on Tuesday, August 23rd. Finally, Argus boosted their target price on shares of Zoetis from $54.00 to $58.00 and gave the company a “below average” rating in a research report on Friday, September 9th. Two research analysts have rated the stock with a sell rating, two have given a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $55.27.
In other news, insider Andrew Fenton sold 13,870 shares of Zoetis stock in a transaction dated Friday, September 2nd. The shares were sold at an average price of $51.25, for a total value of $710,837.50. Following the sale, the insider now owns 17,719 shares of the company’s stock, valued at $908,098.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Michael B. Mccallister bought 2,000 shares of the stock in a transaction dated Tuesday, September 6th. The stock was purchased at an average cost of $51.34 per share, for a total transaction of $102,680.00. The disclosure for this purchase can be found here. 0.05% of the stock is currently owned by insiders.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.